Repligen Stock Valuation

RGEN
 Stock
  

USD 255.73  7.23  2.91%   

What is the current enterprise value of Repligen Cp? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Repligen, is its stock price multiplied by the total number of shares outstanding, calculating Repligen's enterprise value requires a different approach. It uses Repligen's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Free Cash Flow is expected to rise to about 3.9 M this year. Enterprise Value is expected to rise to about 950.6 M this year.
Repligen Cp holds a recent Real Value of $284.48 per share. The prevailing price of the company is $255.73. At this time, the company appears to be undervalued. Our model determines the value of Repligen Cp from analyzing the company fundamentals such as Return On Equity of 9.35 %, shares outstanding of 55.49 M, and Operating Margin of 32.84 % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support picking up undervalued entities and discarding overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
  
Repligen Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Repligen's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Repligen Most Recent Valuation Data

Price Book
7.86
Enterprise Value
14 B
Enterprise Value Ebitda
56.62
Price Sales
17.98
Forward PE
75.76
Trailing PE
89.82
Undervalued
Today 255.73
Please note that Repligen's price fluctuation is very steady at this time. Calculation of the real value of Repligen Cp is based on 3 months time horizon. Increasing Repligen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Repligen Cp is useful when determining the fair value of the Repligen stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Repligen. Since Repligen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Repligen Stock. However, Repligen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
223.65
Downside
284.48
Real Value
288.30
Upside
Estimating the potential upside or downside of Repligen Cp helps investors to forecast how Repligen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Repligen more accurately as focusing exclusively on Repligen's fundamentals will not take into account other important factors:
Earnings
Estimates (7)
LowProjected EPSHigh
2.892.902.91
Details
Hype
Prediction
LowEstimated ValueHigh
242.60246.42250.24
Details
Naive
Forecast
LowNext ValueHigh
245.29249.11252.93
Details
10 Analysts
Consensus
LowTarget PriceHigh
240.00310.33368.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Repligen's intrinsic value based on its ongoing forecasts of Repligen's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Repligen's closest peers. When choosing an evaluation method for Repligen Cp, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Repligen Investments

20.59 Million

Repligen Valuation Drivers Correlation

Many accounts on the financial statements of Repligen Cp are highly interrelated and sometimes correlated. Consequently, when conducting Repligen's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Repligen
Click cells to compare fundamentals

Repligen Valuation Trend

Knowing Repligen's actual value is paramount for traders to make sound investment determinations. Repligen's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Repligen's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Repligen's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Repligen Market Cap

Repligen Cp is currently regarded as top stock in market capitalization category among related companies. Market capitalization of Medical Instruments & Supplies industry is at this time estimated at about 396.24 Billion. Repligen holds roughly 13.79 Billion in market capitalization claiming about 3% of all equities under Medical Instruments & Supplies industry.
Capitalization  Revenue  Valuation  Total debt  Workforce

Repligen Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Repligen's current stock value. Our valuation model uses many indicators to compare Repligen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Repligen competition to find correlations between indicators driving Repligen's intrinsic value. More Info.
Repligen Cp is currently regarded as top stock in beta category among related companies. It is currently regarded as top stock in price to earning category among related companies reporting about  86.19  of Price to Earning per Beta. Price to Earnings Ratio is expected to rise to 85.51 this year. Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to rise to about 233.3 M this year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Repligen by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Repligen's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Repligen's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Repligen's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Repligen and how it compares across the competition.

About Repligen Valuation

The stock valuation mechanism determines the current worth of Repligen Cp on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Repligen Cp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Repligen Cp based exclusively on its fundamental and basic technical indicators. By analyzing Repligen's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Repligen's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Repligen. We calculate exposure to Repligen's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Repligen's related companies.
Fiscal Year End
December
Industry
Medical Instruments & Supplies
Concentration
Biotechnology
Full Time Employees
1.9 K
Service Category
Life Sciences Tools & Services
Employer Id Number
04-2729386
Last ReportedProjected for 2022
Gross Profit51.7 M55.8 M
Profit Margin 19.13  20.64 
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Repligen operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1852 people.

Repligen Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Repligen does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio1.69
Earnings Quarterly Growth37.60%
Revenue Growth27.40%
Enterprise Value To Ebitda54.06
Earnings Growth37.50%
Enterprise Value To Revenue17.75

Repligen Current Valuation Indicators

Valuation refers to the process of determining the present value of Repligen Cp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Repligen we look at many different elements of the entity such as Repligen's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Repligen's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Repligen's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Repligen, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Repligen's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Repligen's worth.
Additionally, take a look at Your Equity Center. Note that the Repligen Cp information on this page should be used as a complementary analysis to other Repligen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Repligen Stock analysis

When running Repligen Cp price analysis, check to measure Repligen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repligen is operating at the current time. Most of Repligen's value examination focuses on studying past and present price action to predict the probability of Repligen's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Repligen's price. Additionally, you may evaluate how the addition of Repligen to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Is Repligen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.38
Market Capitalization
14 B
Quarterly Revenue Growth YOY
0.27
Return On Assets
0.0591
Return On Equity
0.0936
The market value of Repligen Cp is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine Repligen value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.